J.P. Morgan analyst Anupam Rama maintains $Amicus Therapeutics (FOLD.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 48.2% and a total average return of 4.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Amicus Therapeutics (FOLD.US)$'s main analysts recently are as follows:
Amicus' third quarter revenues exceeded Street forecasts, boasting $120.4M from Galafold sales and $21.1M from purchase order sales. Post-results, adjustments were made to the financial model for the quarter, along with an update to the guidance and a shift of the discount year to 2025. Additionally, the cost of goods sold was revised upwards, reflecting management's commentary on inventory expenses for P+O.
Following the report of third-quarter sales surpassing consensus expectations and the company's subsequent increase in fiscal year guidance for Galafold and Pombiliti, the view is that Amicus' narrative may prove to be highly attractive to potential strategic acquirers in 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根大通分析師Anupam Rama維持$愛美醫療 (FOLD.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為48.2%，總平均回報率為4.0%。
此外，綜合報道，$愛美醫療 (FOLD.US)$近期主要分析師觀點如下：
Amicus第三季度的收入超過了華爾街的預期，其中Galafold的銷售額爲1.204億美元，採購訂單銷售額爲2,110萬美元。公佈業績後，對本季度的財務模型進行了調整，並更新了指導方針，並將折扣年份移至2025年。此外，商品銷售成本向上修正，反映了管理層對P+O庫存支出的評論。
繼第三季度銷售額超過市場普遍預期的報告以及該公司隨後提高了對加拉福德和龐比利蒂的財年預期之後，人們認爲Amicus的說法可能會在2025年對潛在的戰略收購方產生極大的吸引力。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
